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N E U R O S C I E N C E
C9orf72-derived arginine-containing dipeptide repeats 
associate with axonal transport machinery and impede 
microtubule-based motility
Laura Fumagalli1,2†, Florence L. Young3†, Steven Boeynaems4†, Mathias De Decker1,2,  
Arpan R. Mehta5,6,7,8, Ann Swijsen1,2, Raheem Fazal1,2, Wenting Guo1,2,9, Matthieu Moisse1,2, 
Jimmy Beckers1,2, Lieselot Dedeene1,2,10,11,12, Bhuvaneish T. Selvaraj5,6,8, Tijs Vandoorne1,2, 
Vanesa Madan3, Marka van Blitterswijk13, Denitza Raitcheva14, Alexander McCampbell14, 
Koen Poesen10,12, Aaron D. Gitler4, Philipp Koch15,16, Pieter Vanden Berghe17, Dietmar 
Rudolf Thal11,18, Catherine Verfaillie9, Siddharthan Chandran5,6,7,8,19,20, Ludo Van Den Bosch1,2, 
Simon L. Bullock3*, Philip Van Damme1,2,21*
A hexanucleotide repeat expansion in the C9orf72 gene is the most common genetic cause of amyotrophic lateral 
sclerosis (ALS) and frontotemporal dementia (FTD). How this mutation leads to these neurodegenerative diseases 
remains unclear. Here, we show using patient stem cell–derived motor neurons that the repeat expansion impairs 
microtubule-based transport, a process critical for neuronal survival. Cargo transport defects are recapitulated by 
treating neurons from healthy individuals with proline-arginine and glycine-arginine dipeptide repeats (DPRs) 
produced from the repeat expansion. Both arginine-rich DPRs similarly inhibit axonal trafficking in adult Drosophila 
neurons in vivo. Physical interaction studies demonstrate that arginine-rich DPRs associate with motor complexes 
and the unstructured tubulin tails of microtubules. Single-molecule imaging reveals that microtubule-bound 
arginine-rich DPRs directly impede translocation of purified dynein and kinesin-1 motor complexes. Collectively, 
our study implicates inhibitory interactions of arginine-rich DPRs with axonal transport machinery in 
C9orf72-associated ALS/FTD and thereby points to potential therapeutic strategies.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia 
(FTD) are adult-onset neurodegenerative diseases that are charac-
terized by the degeneration of motor neurons in the spinal cord, 
brainstem and motor cortex, and neurons in the frontal and ante-
rior temporal cortex, respectively (1, 2). ALS patients present with 
progressive muscle weakness and wasting, whereas FTD patients 
present with behavioral and/or language abnormalities (1, 2). In 
recent years, it has become evident that ALS and FTD belong to a 
spectrum of disorders, sharing some clinical, neuropathological, 
and genetic features (1, 2). A GGGGCC (G4C2) repeat expansion in 
the 5′ noncoding region of the C9orf72 gene is the most common 
genetic cause of both ALS and FTD (C9-ALS/FTD) (3, 4). Three non- 
mutually exclusive pathological mechanisms have been proposed 
for the hexanucleotide repeat expansions (HREs) (5). The first is a 
loss-of-function scenario due to decreased expression of C9orf72 
mRNA and protein observed in C9-ALS/FTD patients. The second 
is an RNA gain-of-function mechanism caused by the accumulation 
of expanded repeat transcripts that sequester numerous RNA-binding 
proteins. The third is a protein gain of function via the generation 
of dipeptide repeat (DPR) proteins originating from non-ATG–
mediated translation of the expanded repeat transcripts.
This repeat-associated non-ATG (RAN) translation occurs in all 
reading frames of sense and antisense transcripts, resulting in five 
DPR proteins: poly-glycine-arginine (GR) and poly-glycine-alanine 
(GA) exclusively from the sense transcript, poly-proline-arginine 
(PR) and poly-proline-alanine (PA) exclusively from the antisense 
transcript, and poly-glycine-proline (GP) from both transcripts (5). 
DPRs are found in cytoplasmic inclusions in C9-ALS/FTD post-
mortem brain and spinal cord tissue and are also detected in motor 
neurons differentiated from patient-derived induced pluripotent 
stem cells (iPSCs) (5, 6). The arginine-rich DPRs—poly-PR and 
poly-GR—are potently toxic in numerous disease models (7–16) 
and cause mitochondrial (17, 18) and endoplasmic reticulum (ER) 
stress (15), as well as disturbances in gene expression, RNA pro-
cessing and translation (7, 19–23), nucleocytoplasmic transport 
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(10, 11, 14, 24, 25), and the dynamics of membrane-less organelles 
(26–28). Whether these effects fully explain the toxicity of arginine- 
rich DPRs in neurons remains unclear.
Of the several other genes that have been associated with ALS 
(29), three encode proteins important for microtubule-based cargo 
transport: the tubulin isotype 4a (30), the plus end-directed kinesin-1 
motor KIF5A (31), and DCTN1, a component of the dynactin 
complex that activates the minus end-directed motor cytoplasmic 
dynein-1 (hereafter dynein) (32). The association of these muta-
tions with ALS suggests that motor neurons, which are selectively 
targeted by the disease, are particularly reliant on efficient cargo 
trafficking, presumably due to their extended processes. This notion 
prompted us to investigate the involvement of microtubule-based 
transport in C9-ALS/FTD.
We observe impaired microtubule-based transport in iPSC- 
derived motor neurons from C9-ALS/FTD patients, including ele-
vated pausing of motile cargoes. We show that exposure to poly-PR 
and poly-GR elicits comparable effects in control iPSC-derived mo-
tor neurons and Drosophila neurons within the intact animal. Inter-
action studies, including in motor neurons and postmortem patient 
tissues, reveal association of arginine-rich DPRs with microtubules 
and motor proteins. We use single-molecule imaging of purified 
components to demonstrate that the arginine-rich DPRs directly 
impede motility by binding both the unstructured tubulin tails of 
microtubules and dynein and kinesin-1 motor complexes. Our data 
strengthen the evidence that defective axonal cargo trafficking con-
tributes to ALS pathogenesis and implicate inhibitory interactions 
of arginine-rich DPRs with the axonal transport machinery in 
C9-ALS/FTD.
RESULTS
Characterization of C9-ALS/FTD motor neurons
To investigate whether C9-ALS/FTD is associated with impaired 
microtubule-based transport, we first generated spinal motor neu-
rons (sMNs) from fibroblast-derived iPSC lines from four C9orf72 
patients and three healthy controls (figs. S1 to S3 and table S1). Mo-
lecular analysis of C9orf72 cell lines revealed expansions of ~180 to 
770 hexanucleotide repeats (fig. S2B). With the exception of a 
slightly elevated rate of neurite outgrowth (fig. S3F), C9orf72 neu-
rons developed indistinguishably to the controls. Immunostaining 
showed that the C9orf72 lines produced motor neurons with similar 
efficiency to control lines at day 38 of the in vitro differentiation 
(fig. S3). Whole-cell patch clamp recordings of evoked and sponta-
neous action potentials at the same time point demonstrated func-
tional maturation of both control and C9orf72 sMN lines, with no 
differences in electrical activity between the genotypes (fig. S4 and 
table S2). This finding is in line with previous studies using iPSC- 
derived sMNs (33, 34).
We next investigated potential loss-of-function mechanisms in 
the sMNs by assessing C9orf72 mRNA levels using digital droplet 
quantitative reverse transcription polymerase chain reaction (qRT-
PCR). Although there were some subtle differences in the relative 
levels of specific C9orf72 transcript variants between patient and 
control sMNs, there were no differences in overall C9orf72 mRNA 
levels (fig. S5, A to D). Immunoblotting showed that levels of 
C9orf72 protein were also not significantly different between 
patient-derived lines and controls (fig. S5, E and F). We did, however, 
detect both poly-GA and poly-GP specifically in the C9orf72 lines 
using an enzyme-linked immunosorbent assay (ELISA) (fig. S5G), 
confirming that RAN translation is occurring in these cells.
C9orf72 hexanucleotide expansions impair  
microtubule-based transport in motor neurons
Defective microtubule-based transport of mitochondria in axons 
has been linked with a variety of neurodegenerative diseases, in-
cluding ALS caused by other mutations (35). We therefore assessed 
motility of these organelles by live imaging of C9orf72 and healthy 
control motor neuron lines incubated with the mitochondrial stain 
MitoTracker. Kymograph-based analysis of neurons that had been 
differentiated for 38 days revealed that the proportion of mitochon-
dria undergoing transport in neurites was reduced in the C9orf72 
lines (Fig. 1, A and B, and fig. S6, A to D). The total number of mi-
tochondria in neurites was also lower in C9orf72 lines (fig. S6D), a 
phenomenon previously observed when microtubule motors are 
inhibited in neurons due to a deficit in motor-driven export of these 
organelles from the soma (36, 37). Furthermore, a greater propor-
tion of the mitochondria that were motile in neurites paused during 
or at the end of processive movements in the C9orf72 lines com-
pared to the control lines (Fig.  1C). We also observed impaired 
transport of RNA granules [which were labeled with the SYTO-RNA 
Select dye (38)] in the C9orf72 sMNs at 38 days of differentiation 
(fig. S7). We next investigated the time course of transport deficits 
in the patient-derived neurons. Impaired motility of MitoTracker- 
stained mitochondria developed over time in culture (not evident at 
days 25 and 30) and persisted in older C9orf72 neurons (day 52) 
(Fig. 1D and fig. S8). Collectively, these data reveal an age-related 
onset of transport deficits in the patient-derived neurons.
The dense nature of the neuronal cultures meant that we were 
unable to assign anterograde and retrograde movements when 
mitochondria in all neurons were labeled with MitoTracker. We 
therefore visualized mitochondria in a subset of neurons using 
sparse infection with lentivirus expressing mitoDsRed2. This analy-
sis showed that both anterograde and retrograde motion was im-
paired in C9orf72 neurons (Fig. 1, E and F). These experiments were 
performed in independent C9orf72 iPSC lines using isogenic con-
trols in which the repeat expansion had been corrected by CRISPR/
Cas9 gene editing (33). We conclude from these observations that 
the C9orf72 repeat expansion impairs both anterograde and retro-
grade motion.
Arginine-rich DPRs disrupt microtubule-based 
transport in sMNs
As introduced above, there is compelling evidence that arginine- 
rich DPRs produced by C9orf72 HREs contribute to pathophysiology 
(7–15, 18, 24, 25). We therefore tested whether these molecules are 
sufficient to recapitulate the transport deficits observed in C9orf72 
patient–derived motor neurons. We added peptides containing 
20 repeats of PR or GR (PR20 and GR20) to the culture medium of 
control iPSC-derived sMNs. Consistent with previous observations 
(8, 15), these peptides were taken up by the neurons (fig. S9, A to C). 
We observed a reduced frequency of mitochondrial transport in 
neurons upon overnight treatment with arginine-rich DPRs at con-
centrations that did not trigger cell death (Fig. 2, A, C, and D, and 
figs. S9D and S10, D to I). As was observed in C9orf72 neurons, 
sMNs treated with arginine-rich DPRs also had a reduction in the 
number of mitochondria in neurites (fig. S10, F and I). Treated neu-
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or at the end of a processive movement (Fig. 2, E and F), which was 
also a feature of the C9orf72 lines (Fig. 1C).
To investigate the effect of repeat length on transport, we treated 
sMNs with PR30. Dose-response experiments revealed that PR30 
was more potent than PR20 in our assay, significantly reducing 
mitochondrial motility upon overnight treatment with a concentra-
tion in the medium as low as 0.1 M (Fig. 2G and figs. S11 and S12). 
We also evaluated the effect of a prolonged exposure of peptides on 
transport, finding that 3 days of incubation with poly-GR or poly- 
PR also impaired transport in a dose-dependent manner (Fig. 2G 
and figs. S11 and S13). Whereas overnight treatment with PR30 par-
tially inhibited motility, 3 days of incubation with this peptide pre-
vented all transport, indicating stronger inhibition with increasing 
exposure time. Delivery into neurons of poly-GP (GP20), which was 
nontoxic in other studies (10, 26, 27) and in this one (fig. S9D), did 
not affect motility of mitochondria (Fig. 2, A and B, and figs. S10, A 
to C, and S13, E to H). As was observed in untreated C9orf72 lines, 
control motor neurons treated with arginine-rich DPRs had im-
paired transport of RNA granules (fig. S14, A and F to O). This ef-
fect was not observed with poly-GP (fig. S14, A to E). Collectively, 
these observations show that arginine-rich DPRs inhibit transport 
in human sMNs and that the effects on motility are similar to those 
observed in C9orf72 patient–derived neurons.
Microtubule-based transport in adult Drosophila is impaired 
by arginine-rich DPRs
We next explored the effect of poly-GR and poly-PR on axonal 
transport in vivo. We used a previously described adult Drosophila 
model, in which microtubule-based movements of green fluores-
cent protein (GFP)–labeled mitochondria are visualized in wing 
nerve axons of immobilized flies (Fig. 3, A and B) (36). Here, as in 
other axons (37, 39), anterograde and retrograde mitochondrial 
movements are driven by kinesin-1 and dynein motors, respectively 
(36). There was a decrease in the frequency of axonal transport of 
mitochondria upon transgenic expression of poly-PR and poly-GR 
in wing neurons (Fig. 3, B and C). This effect was evident in both the 
anterograde and retrograde directions (fig. S15, A and B). Arginine- 
rich DPRs also increased the incidence of mitochondria pausing within 
or at the end of a processive movement (Fig. 3, B and D), as was 
observed in human sMNs treated with these peptides or derived from 
C9-ALS/FTD patients (Figs. 1C and 2, E and F). Poly-GA, which 
is relatively highly expressed from C9orf72 repeat expansions (40), 
did not affect mitochondrial trafficking when expressed in the wing 
nerve (Fig. 3, C and D). These observations show that arginine-rich 
DPRs are sufficient to impair bidirectional cargo transport in vivo.
We next used Drosophila to investigate whether transport 










































































Fig. 1. The C9orf72 HRE impairs mitochondrial transport in sMN neurites. (A) Example kymographs (time-distance plots) of mitochondria (MitoTracker Red) from 
38-day-old control (CON) and C9orf72 (C9) sMNs. Scale bars, 50 s and 30 m. (B) Percentage of mitochondria that are motile in sMNs (day 38). (C) Percentage of all motile 
mitochondria that undergo pausing (day 38). (D) Percentage of all mitochondria that are motile at different days of differentiation [day 38 data reproduced from (B)]. 
(E and F) Percentage of mitochondria (mitoDsRed2) transported anterogradely (E) or retrogradely (F) in 38-day-old C9orf72 sMNs or isogenic paired controls with excision 
of the HRE. Two independent healthy controls are shown for comparison. Difference in magnitude of transport deficits compared to (B) may be related to different 
mitochondrial labeling methods. Data represented as means ± SD; dots represent values for individual neurites (see table S3 for numbers of neurites analyzed). Statistical 
significance was evaluated with a Mann-Whitney U test (B to D) or a Kruskal-Wallis test with Dunn’s multiple comparison (E and F) (*P < 0.05; **P < 0.01; ***P < 0.001; 
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took previously established models in which poly-GR and poly-PR 
are expressed in other tissues of the fly (9) and asked if the pheno-
types are exacerbated by reducing motor gene dosage (Fig. 3E, 
fig. S16, and table S4). Inactivating one copy of the Khc gene, which 
encodes the kinesin-1 heavy chain, strongly enhanced the lethality 
(Fig. 3E and table S4) and eye defects (fig. S16) associated with 
expression of these DPRs. Control experiments indicated that the 
modification of arginine-rich DPR toxicity was due to the mutant 
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Fig. 2. Arginine-rich DPRs impair mitochondrial transport in sMNs of healthy individuals. (A) Example kymographs after treatment of control neuron with synthetic 
GP20, GR20, or PR20 (1.5 and 3 M). Scale bars, 50 s and 30 m. (B to D) Percentage of all mitochondria that are motile upon treatment with GP20, GR20, or PR20. (E and 
F) Percentage of all motile mitochondria that undergo pausing after treatment with GR20 or PR20. (G) Percentage of all mitochondria that are motile after 16- or 72-hour 
treatment with PR20 or PR30 (0.1 or 0.5 M). Data represented as means ± SD; dots represent values for individual neurites (see table S3 for numbers of neurites analyzed). 
Statistical significance was evaluated with a Kruskal-Wallis test with Dunn’s multiple comparison (B to D and G) or a Mann-Whitney U test (E and F) [*P < 0.05; **P < 0.01; 
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Khc allele and not another mutation in the genetic background 
(fig. S16). The enhancement of the poly-GR and poly-PR phenotypes 
by reducing Khc gene dosage is consistent with the contribution of 
transport defects to the toxicity of the peptides.
Arginine-rich DPRs interact with microtubules 
and motor proteins
Arginine-rich DPRs might interfere with the transport machinery 
directly or by perturbing another cellular process that is indirectly 
required for efficient trafficking. To determine whether direct bind-
ing of arginine-rich DPRs to the microtubule-based transport ma-
chinery could be behind the axonal transport defects, we first asked 
if PR30 interacts with tubulin or microtubule motors in mouse 
spinal cord lysate. As previously observed with cancer cell extracts 
(26), incubating the soluble fraction of the spinal cord lysate with 
PR30 peptide, but not GP30, led to the formation of large biomo-
lecular condensates that could be pelleted by gentle centrifugation 
and analyzed by mass spectrometry (Fig. 4, A to C). The spinal 
cord interactome of PR30 was strongly enriched for gene ontology 
(GO) categories (e.g., RNA granule, translation, proteasome, and 
protein folding) present in the cancer cell interactome (Fig. 4C; fig. 
S17, A and B; and table S5) (26). We also identified a strong enrich-
ment of terms related to intracellular transport (Fig. 4, C and D). In 
addition to factors involved in nucleocytoplasmic transport, a 
process we and others previously implicated in C9-ALS/FTD 
(10,  11,  14,  24), this category included many proteins involved in 
microtubule-based transport (Fig. 4C and table S5). Several iso-
types of the - and -tubulin subunits of microtubules were pre-
cipitated with PR30 (Fig.  4D and table S5), as were the three 
different kinesin-1 isoforms (Kif5A, Kif5B, and Kif5C) and com-
ponents of the dynein and dynactin complexes (Fig. 4D and table 
S5). We also detected other classes of kinesins and components 
of intraflagellar transport dynein (cytoplasmic dynein-2) in 
the precipitate (Fig. 4D and table S5). These data reveal that PR30 
can associate in spinal cord lysate with multiple proteins involved in 



















































































































































Fig. 3. Mitochondrial transport in adult Drosophila axons is impaired by arginine-rich DPRs. (A) Cartoon of Drosophila wing. Green box, imaged region containing 
bundled axons from multiple neurons. (B to D) Effects of arginine-rich DPRs on transport of mitochondria (mito::GFP) in 2-day-old males (mito::GFP and peptides were 
expressed specifically in chemosensory neurons with dpr-Gal4). Control, no DPR expression. (B) Example stills of mitochondria and traces of transport events in corre-
sponding movies. Blue, retrograde tracks; magenta, anterograde tracks; circles, starting locations; vertical lines, pausing sites. Scale bar, 10 m; movie duration, 3 min. 
(C) Percentage of all mitochondria that are motile. (D) Percentage of all motile mitochondria that undergo pausing. (E) Effect of Kinesin-1 heavy chain (Khc) gene dosage 
on GR36-induced lethality (scored 4 to 6 days after eclosion). Data expressed as percentage of offspring expected when there is no lethality. Khc27, kinesin-1 null allele. In 
(C) to (E), means ± SD are shown; dots represent values for individual wings (C and D) or individual egg lays (E) (see table S4 for numbers analyzed). Statistical significance 
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these factors are mutated in ALS or other neuromuscular disor-
ders (Fig. 4D, fig. S17A, and table S5).
The association of arginine-rich DPRs with kinesin-1, dynein, 
and microtubules was further supported by immunoprecipitations 
from human iPSC-derived sMNs treated with hemagglutinin 
(HA)–tagged PR20, GR20, and GP20 peptides (Fig. 4E and fig. S17, C 
to E). In these experiments, robust signals for KIF5B, tubulin, and 
dynein were observed in immunoblots of the material precipitated 
with PR20 and GR20, but not in the material precipitated with GP20.
We next investigated interactions of DPRs with microtubules 
and motors within intact sMNs using fluorescence microscopy. The 
broad distribution of microtubules, KIF5B, and dynein within cell 
bodies and along neuronal processes prevented meaningful analysis 
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Fig. 4. Arginine-rich DPRs interact with axonal transport machinery. (A) Overview of mass spectrometry experiment. (B) Silver stain of pellet fractions. PR30, but not 
GP30, induces protein phase separation. (C) The PR30 interactome (n = 1811) is enriched for GO categories centered on protein metabolism (including factors involved in 
translation, folding, and degradation) and intracellular transport. (D) Illustration of components of axonal transport machinery present in PR30 interactome (GO CC, GO 
analysis cellular compartment; GO MF, GO analysis molecular function). Proteins associated with ALS/FTD or other neuromuscular disorders are highlighted in red and 
blue, respectively. (E) Immunoblots confirming interactions of KIF5B, dynein, and tubulin with PR20 and GR20, but not GP20, in human sMN lysates (uncropped blots shown 
in fig. S17, C to E). In (B) and (E), the input was diluted 1:10 before gel loading. (F) Immunofluorescence of frontal cortex from C9orf72 patients showing examples of 
enrichment of KIF5B in poly-GR aggregates. ALS patients without a C9orf72 expansion were used as controls. Scale bar, 5 m. (G) Quantification of colocalization of 
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colocalization analysis. However, colocalization of signals from 
poly-PR and tubulin could be detected in growth cones of developing 
sMNs, in which microtubule signals are spaced apart (fig. S18A). 
Furthermore, duolink proximity ligation assays (PLAs) supported 
the interaction between PR20 and KIF5B in both the cell body and 
processes of sMNs (fig. S18B). We also investigated the association 
of the transport machinery with endogenously expressed arginine- 
DPRs in postmortem tissue from patients with C9-ALS/FTD. We 
detected enrichment of KIF5B in 25 to 40% of cytoplasmic poly-GR 
inclusions in frontal cortex sections of all five patients analyzed 
(Fig. 4, F and G, and fig. S19A). Consistent with previous obser-
vations (41), GR inclusions were rare in spinal cord. The paucity of 
these structures in spinal cord prevented a meaningful quantifica-
tion of their colocalization with KIF5B, although we did find instanc-
es of such events (fig. S19B). Collectively, our mass spectrometry, 
immunoprecipitation, and immunofluorescence data support phys-
ical association of arginine-rich DPRs with the axonal transport 
machinery.
Microtubule-based transport is perturbed by arginine-rich 
DPRs in a reconstituted in vitro system
We next asked if arginine-rich DPRs directly impair the transloca-
tion of motors along microtubules using in vitro motility assays 
with purified components. Kinesin-1 and dynein were chosen for 
these experiments because, as introduced above, they are the major 
motors for mitochondrial transport in axons (37, 39). These motors 
are also important for the transport of RNA granules in neuronal 
processes (42). To evaluate kinesin-1 motility, we used a well- 
characterized, constitutively active form of the major human iso-
form KIF5B tagged with GFP (43). Dynein motility assays were 
performed with a tetramethylrhodamine (TMR)–labeled human 
recombinant motor complex in the presence of the essential activa-
tors dynactin and BICD2N (44). Stabilized microtubules were bound 
to a glass surface and incubated with concentrations of motor com-
plexes low enough for visualization of single transport events by 
total internal reflection fluorescence (TIRF) microscopy.
We first assessed the effects of 20-repeat DPRs on motility of 
KIF5B by introducing them into the motility assay together with the 
motor complex (Fig. 5A). GR20 and PR20 significantly reduced the 
percentage of microtubule-associated KIF5B complexes exhibiting 
processive transport compared to the control in which no pep-
tides were added (Fig. 5B). These DPRs also caused a decrease in the 
mean velocity of processive KIF5B movements, as well as an in-
crease in the incidence of pausing events within or at the end of a 
run (Fig. 5B). GR20 and PR20 had the same consequences on the 
motility of dynein in the presence of dynactin and BICD2N, al-
though the magnitude of these effects relative to the no-peptide 
control tended to be smaller than observed for KIF5B (Fig. 5C). In 
contrast, GP20 did not reduce the percentage of processive events 
or velocity of either motor, or increase their incidence of pausing 
(Fig. 5, A to C).
Given the strong inhibition of mitochondrial transport in motor 
neurons by 30 repeats of PR (Fig. 2G and figs. S11 and S12), we also 
tested the effect of this peptide on purified KIF5B and dynein 
complexes. Compared to controls lacking peptide, PR30 impaired 
processive movements of both KIF5B and dynein complexes in a 
dose-dependent manner (Fig. 5, D and E, and fig. S20, A and B). 
The effect of PR30 on dynein was proportionally stronger than ob-



































































































































































































































































































Fig. 5. Arginine-rich DPRs perturb KIF5B and dynein motility in a reconstituted 
in vitro system. (A) Example kymographs of KIF5B and dynein in the presence of 
10 M GP20, GR20, PR20, or no peptide (control). The activating cofactors dynactin 
and BICD2N were present for all dynein experiments. Scale bars, 10 s and 5 m; 
microtubule plus end to the right. (B and C) Effects of 10 M GP20, GR20, or PR20 on 
percentage of microtubule-bound motors that are processive, velocity of proces-
sive movements, and percentage of processive complexes that undergo pausing. 
(D and E) Effects of poly-PR chain length and concentration on percentage of 
microtubule-bound motors that are processive. In (D) and (E), values for 10 M PR20 
and control are reproduced from (B) and (C) to facilitate comparison. In (B) to (E), 
means ± SD are shown; dots represent values for individual microtubules (see table 
S6 for numbers of microtubules and motor complexes analyzed). Statistical signifi-
cance was evaluated with a one-way ANOVA multiple comparisons test with 
Dunnett’s correction (B and C) or Tukey’s correction (D and E) (*P < 0.05; **P < 0.01; 
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impaired KIF5B motility to a similar extent (Fig. 5D and fig. S20D). 
Upon further analysis, we found additional differences in the effect 
of arginine-rich DPRs on KIF5B and dynein. First, there were more 
overall binding events of KIF5B on microtubules in the presence of 
GR20, PR20, and PR30 compared to no peptide controls (figs. S20D 
and S21A), whereas there were fewer such events for dynein relative 
to the control (figs. S20C and S21B). Second, while the arginine-rich 
DPRs prolonged the duration of processive movements for KIF5B, 
the opposite was true for processive dynein complexes (fig. S21). 
Collectively, our experiments demonstrate that arginine-rich DPRs 
perturb motility of both dynein and KIF5B in the absence of other 
potentially confounding cellular processes, although the effects of 
the peptides on the interactions of the two motors with microtu-
bules are not equivalent.
Microtubule-associated arginine-rich DPRs directly impede 
motor movement
To shed light on how arginine-rich DPRs impair motor movement, 
we monitored their localization in the in vitro motility assay. 
Consistent with our previous analysis using mouse spinal cord and 
human sMNs, there was a clear interaction of fluorescently labeled 
GR20, PR20, and PR30 with microtubules (Fig. 6A). All three pep-
tides bound along the length of the lattice but were also concentrat-
ed in puncta (Fig. 6A). The strongest overall binding was exhibited 
by PR30 (Fig. 6B), which also had more frequent and more intense 
puncta than the 20-repeat DPRs (Fig. 6A). No microtubule associa-
tion was observed for GP20 (Fig. 6, A and B). Thus, only those DPRs 
that perturb motility of KIF5B and dynein in the in vitro motility 
assay can associate with microtubules.
We next investigated which features of microtubules are required 
for binding to arginine-rich DPRs. Tubulin proteins comprise a 
folded core and a negatively charged, unstructured C-terminal tail 
that faces the bulk cytoplasm in the assembled microtubule. Microtu-
bules formed from tubulin dimers with tails subsequently removed 
by the enzyme subtilisin (45) did not interact with poly- GR or po-
ly-PR (Fig. 6B and fig. S22, A and B). This result demonstrates that 
the interaction of arginine-rich DPRs with microtubules is mediat-
ed by the tubulin tail.
These observations raised the possibility that tubulin tail–associated 
DPRs inhibit transport by acting as obstacles for KIF5B and dynein. 
Reducing the concentration of PR30 led to clearly resolvable puncta 
on microtubules (fig. S22C) that allowed us to investigate discrete 
interactions of DPRs and motor complexes on microtubules. We 
quantified the coincidence of sites of motor pausing or microtubule 
detachment with the patches of intense PR30 accumulation. To 
account for the probability that pausing events occurred at sites of 
PR30 foci by random chance, we overlaid motor trajectories on 
patterns of PR30 foci from different microtubules or microtubule 
regions from the same experiment (Fig. 6, C to F). These analyses 
showed that pause sites and detachment sites for both motors coin-
cided with a patch of PR30 significantly more often than expected by 
random chance (Fig. 6, D and F). We conclude that large accumu-
lations of arginine-rich DPRs can act as obstacles to KIF5B and 
dynein complexes. Our observation that the velocity of both motors 
along the microtubule was persistently reduced by poly-GR and 
poly-PR (Fig. 5, B and C) suggests that the more uniform binding of 
these DPRs along the rest of the lattice also impairs motility.
We additionally detected instances of each type of motor com-
plex transporting large foci of PR30 along microtubules [Fig. 6G; 
observed for 1.8% of processive KIF5B complexes (3 of 169) and 
8.1% of processive dynein complexes (9 of 111)]. These observa-
tions indicate that, in addition to associating with microtubules, 
PR30 can interact with KIF5B and dynein-dynactin-BICD2N com-
plexes in our reconstituted system. This finding is consistent with 
our observation that arginine-rich DPRs can interact with both tu-
bulin and motors in the cellular environment (Fig. 4, A to E).
In summary, our single-molecule experiments reveal that inter-
actions of arginine-rich DPRs with tubulin tails and motors impede 
transport along the microtubule track (schematized in Fig. 7). This 
mechanism offers an explanation for the decreased frequency of 
transport and increased incidence of pausing exhibited by motile 
mitochondria in neurons exposed to arginine-rich DPRs (Figs. 2 
and 3) or derived from C9-ALS/FTD patients (Fig. 1).
DISCUSSION
Axonal transport of organelles and macromolecules by microtubule 
motors is crucial for neuronal homeostasis and survival. This pro-
cess facilitates communication between synaptic terminals and the 
cell body and allows local demands for the functions of organelles 
and macromolecules to be met (35). Inefficient microtubule-based 
transport in axons is linked with several age-related neurodegener-
ative diseases including Alzheimer’s, Huntington’s disease, and 
hereditary spastic paraplegia (35), as well as with ALS caused by 
mutations in SOD1, TARDBP, and FUS (35, 46, 47). However, 
whether impaired axonal transport is a cause or consequence of 
neuronal dysfunction in these contexts remains controversial.
The notion that defective intracellular trafficking can directly 
trigger ALS has been strengthened by the discovery of disease-causing 
mutations in several genes encoding components of the microtubule- 
based transport machinery, namely, TUBA4A, DCTN1, and KIF5A 
(30–32). These mutations have been reported to disturb the dynam-
ics of microtubules or the trafficking of cargos along them (48). De-
spite evidence of defective axonal transport in other forms of ALS, 
the literature on C9-ALS/FTD has focused on other potential dis-
ease mechanisms (5). Here, we report that the disease-causing 
HREs in the C9orf72 gene impair transport of mitochondria and 
RNA granules in neurites of human iPSC-derived sMNs. While our 
study was in review (and posted as a preprint), another group 
reported impaired microtubule-based trafficking of lysosomes in 
C9orf72 neurons (49). Collectively, these data indicate that deficits 
in intracellular trafficking of cargos are a common feature of ALS 
pathogenesis.
Although both loss- and gain-of-function disease mechanisms 
have been proposed in C9-ALS/FTD (5, 49), the transport impair-
ment in our patient-derived motor neurons was not associated with 
a reduction in overall C9orf72 mRNA and protein levels. However, 
we found that administration of the arginine-rich DPRs that are 
produced from C9orf72 HREs dose dependently inhibits transport 
of mitochondria and RNA granules in sMNs derived from healthy 
individuals. Transport deficits become stronger with increasing 
numbers of repeats, raising the possibility that the longer DPRs that 
have been proposed to exist in patients (50) are more potent inhib-
itors of transport. We also observed that both poly-GR and poly-PR, 
but not poly-GA, reduced mitochondrial transport in axons of the 
intact adult Drosophila wing nerve. These observations, which are 
in line with the ability of PR36 to inhibit mitochondrial motility 
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Fig. 6. Arginine-rich DPRs bind microtubules and promote motor pausing and detachment. (A) Example images of microtubules incubated with arginine-rich DPRs. 
Arrowheads, intense peptide puncta. Scale bar, 2.5 m. (B) Background-subtracted DPR signals ± subtilisin treatment. a.u., arbitrary units. (C to F) Analysis of localization 
of intense PR30 puncta with pausing or microtubule detachment events of motile motors (dynein experiments included dynactin and BICD2N). White and yellow arrow-
heads in kymographs show examples of, respectively, pausing and detachment events of motors localizing with PR30 foci. In (D) and (F), simulated controls were gener-
ated by overlaying motor trajectories with PR30 binding patterns from different microtubules or microtubule regions. (G) Kymographs showing examples (arrowheads) of 
translocation of PR30 puncta by motors. In all kymographs: scale bars, 10 s and 2.5 m and microtubule plus end to the right. Chamber concentration of DPRs, 10 M (A 
and B) and 1 M (C to G). In (B), (D), and (F), means ± SD are shown; dots represent values for individual kymographs (see table S6 for number of pausing and detachment 
events analyzed). Statistical significance was evaluated with a one-way ANOVA multiple comparisons test with Tukey’s correction (B) or a Mann-Whitney U test (D and F) 









Fumagalli et al., Sci. Adv. 2021; 7 : eabg3013     9 April 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
10 of 20
gain-of-function mechanism in neurons involving inhibition of 
fundamental transport processes. The relevance of perturbed 
microtubule-based transport to the toxicity of arginine-rich DPRs 
is supported by our finding that reducing kinesin-1 gene dosage en-
hances the detrimental effects of arginine-rich DPRs in flies.
Our in vitro motility assays reveal that poly-GR and poly-PR can 
directly perturb microtubule-based transport of kinesin-1 and 
dynein, which are key motors in the trafficking of many cargos in 
neurons, including mitochondria and RNA granules. These pep-
tides have a range of effects on motor behavior, including reducing 
the fraction of microtubule-associated complexes that are proces-
sive, as well as slowing the movement of complexes and increasing the 
likelihood of arresting during movement. We show that arginine- 
rich DPRs can associate with microtubules through an interaction 
with the C-terminal tubulin tails. The association of arginine-rich 
DPRs with the unstructured tubulin tails is in keeping with their 
propensity to bind intrinsically disordered regions in other proteins 
(26–28). Within the microtubule, tubulin tails face the bulk cyto-
plasm and participate in the interaction with dynein and kinesin 
motors (52). We show using purified proteins that arginine-rich 
DPRs bound to these sites act as obstacles for kinesin-1 and dynein, 
stimulating motor pausing or detachment (Fig. 7). Consistent with 
a physiological role for this mechanism, we found that arginine-rich 
DPRs also increase pausing of motile mitochondria in human sMNs 
and fly wing neurons. A similar increase in the incidence of mito-
chondrial pausing was also observed in sMNs derived from patients 
with C9-ALS/FTD, strengthening the evidence that inhibitory in-
teractions of arginine-rich DPRs with the transport machinery are 
relevant for the disease.
The behaviors of arginine-rich DPRs on microtubules are remi-
niscent of the ability of the MAPT (tau) protein to partition into 
patches on microtubules and obstruct the motility of kinesin-1 and 
dynein complexes in vitro (53). Mutations in both MAPT and 
C9orf72 have been shown to cause FTD, and it was recently proposed 
that this reflects a shared inhibitory effect on nucleocytoplasmic 
transport (54). The ability of both arginine-rich DPRs and MAPT to 
impede the motors responsible for trafficking in the cytoplasm 
offers another possible explanation for the overlapping features of 
C9-ALS/FTD and MAPT-FTD. Whether arginine-rich DPRs, like 
MAPT (55), can potentially also interfere with transport by modu-
lating microtubule stability and dynamics is an interesting topic for 
future research.
We also detect physical association of arginine-rich DPRs with 
kinesin-1 and components of the dynein-dynactin transport com-
plex, which could also contribute to the inhibition of transport. The 
reduced velocity and increased pausing of both types of motor in 
the presence of arginine-rich DPRs in vitro is compatible with their 
retardation by transient interactions with tubulin tail–associated 
peptides. Not all properties of KIF5B and dynein are affected equiv-
alently by arginine-rich DPRs. While the peptides increase the 
frequency of KIF5B binding to microtubules and the duration of its 
processive runs, the opposite is true for dynein. These observations 
indicate that overall interactions of KIF5B and dynein complexes 
with microtubules are increased and decreased, respectively, by 
arginine-rich DPRs. While the mechanistic basis of this differential 
effect warrants further investigation, our results highlight how 
either strengthening or weakening interactions with microtubules 
can prevent efficient translocation of motors along the track.
Given the widespread roles of kinesin-1 and dynein in intracel-
lular transport, as well as our discovery of other classes of microtu-
bule motors in the PR30 interactome from sMNs, it is likely that the 
trafficking of several cargos is disrupted by arginine-rich DPRs. In 
line with this, we found that transport of both mitochondria and 
RNA granules is inhibited in the C9orf72 lines and these changes 
are recapitulated in healthy sMNs treated with poly-PR and poly- 
GR. As described above, it was recently reported that lysosome 
trafficking is also impaired in neurons with the C9orf72 HRE (49). 
Whether altered translocation of a specific cargo type is of particu-
lar significance for C9-ALS/FTD remains to be resolved. It is con-
ceivable that additive effects from disrupting transport of multiple 
cargoes are at work.
While our results support a direct inhibitory effect of arginine- 
rich DPRs on axonal transport, it is possible that other processes 
also contribute to the trafficking defects we observe in C9-ALS/FTD 
neurons. In addition to defective nucleocytoplasmic transport, 
altered RNA splicing, gene expression, translation, and membrane- 
less organelle dynamics, as well as ER stress and bioenergetic defects 
of mitochondria, have been linked to the disease (7, 10, 11, 14, 15, 17–
24, 27, 28, 56). The relative contribution of transport deficits versus 
other pathological effects of C9orf72 mutations remains an open 
question. Addressing this issue will require the development of new 
tools to stimulate cargo transport in patient-derived neurons or 
abrogate arginine-rich DPR binding to tubulin tails. Nonetheless, 
our data raise the possibility that manipulating axonal transport 
machinery could be an effective strategy to hinder the progression 
of C9-ALS/FTD.
MATERIALS AND METHODS
All experiments involving genetically modified organisms, animals, 
or human tissues were approved and overseen by the relevant Insti-
tutional Review Boards and complied with national regulations.
Fig. 7. Working model for how arginine-rich DPRs inhibit microtubule-based 
motor complexes. The arginine-rich DPRs bind microtubules via the C-terminal 
tails of tubulin (right; inset). In addition to binding along the length of the micro-
tubule lattice, the peptides concentrate in large, microtubule-associated foci 
(green circle). When dynein (shown here with dynactin and BICD2 as an example 
cargo adaptor) and KIF5B encounter these foci, interactions between the motors 
and arginine-rich DPRs facilitate motor arrest or detachment (in the crowded 
cellular environment, detached motors are also likely to be static). Molecular 
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Cell culture and motor neuron differentiation
C9orf72 iPSC lines were generated from dermal fibroblasts from 
ALS (C9-2B and C9-3B) and ALS/FTD (C9-1B and C9-4B) patients 
carrying the G4C2 repeat expansion in the C9orf72 gene (for clinical 
information, see table S1). Skin fibroblasts were obtained from 
patients and controls after informed consent and approval by the 
Ethics Committee of the University Hospitals Leuven. Controls 
were generated from unrelated healthy individuals. Con 1B and 
Con 2B were purchased from Takara Bio Inc. (ChiPSC-6b, P11031) 
and Sigma-Aldrich (iPSC Epithelial-1, IPSC0028), respectively. 
Con 3B, C9-1B, C9-2B, C9-3B, and C9-4B were generated using the 
CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher 
Scientific). qRT-PCR for Sendai virus clearance was performed, 
and no residual Sendai virus RNA was detected in any of the tested 
iPSC lines. iPSCs were kept in Essential 8 flex medium (Gibco) with 
penicillin-streptomycin (1000 U/ml). Colonies were passaged every week 
with 0.5 mM EDTA (Invitrogen) diluted in Dulbecco’s phosphate- 
buffered saline (DPBS; Sigma-Aldrich) and plated on Geltrex 
LDEV-Free, hESC-Qualified, Reduced Growth Factor Basement 
Membrane Matrix (Gibco). The absence of mycoplasma contami-
nation was routinely confirmed by PCR. Controls (Con-1B, Con-2B, 
and Con-3B) and C9orf72 (C9-1B, C9-2B, C9-3B, and C9-4B) iPSCs 
were differentiated into sMNs as previously described (46, 57). The 
controls (Con-1 and Con-2), the isogenic controls (C9-1∆, C9-2∆, 
C9-3∆), and the C9orf72 counterparts (C9-1, C9-2, and C9-3) were 
obtained and differentiated as reported by Selvaraj et al. (33).
Immunocytochemistry
Coverslips were incubated for 20 min at room temperature in PBS 
with 4% paraformaldehyde and washed three times with PBS. Cells 
were incubated for 1 hour at room temperature in PBS containing 
0.1% Triton X-100 (Acros Organics) and 5% donkey (Sigma- 
Aldrich) or goat (Dako) serum. Cells were incubated with primary 
antibodies diluted in PBS containing 0.1% Triton X-100 and 2% serum 
overnight at 4°C. Cells were rinsed three times in PBS before the 
secondary antibody was added for 1 hour at room temperature. See 
table S7 for details of primary and secondary antibodies. After 
washing with PBS, the coverslips were incubated for 20 min in PBS/ 
4′,6-diamidino-2-phenylindole (DAPI) (NucBlue Live ReadyProbes 
Reagent, Invitrogen). Coverslips were rinsed three times with PBS 
before mounting in ProLong Gold antifade reagent (Invitrogen). 
Confocal images were obtained with a Leica SP8 DMI8 confocal 
microscope. Images were analyzed, formatted, and quantified with 
ImageJ software.
Pluripotency characterization
iPSCs were subjected to spontaneous differentiation mediated by 
the formation of embryoid bodies (EBs) and subsequently analyzed 
for three-lineage differentiation using the ScoreCard methodology 
(Thermo Fisher Scientific). On the day of EB formation, 60 to 80% 
confluent iPSCs were washed with PBS and incubated with 0.5 mM 
EDTA (Invitrogen) for 1 to 3 min to dissociate the colonies. Cells 
were harvested in Essential 8 flex medium (Gibco) and counted 
before gently spinning down at 300g for 5 min. Cells were plated in a 
24-well Corning Ultra-Low Attachment Surface plates (Corning) at 
a density of 1.5 × 106 cells per well. The plates were incubated over-
night at 37°C. The following day, half of the Essential 8 flex medium 
was replaced with Essential 6 medium (Gibco). For the spontaneous 
differentiation, EBs were kept for 14 days in E6 medium, which was 
changed every 2 days. After 14 days in culture, EBs were collected 
for RNA extraction with the GenElute Mammalian Total RNA Kit 
(Sigma-Aldrich). Complementary DNA (cDNA) synthesis was 
performed with SuperScript III (Thermo Fisher Scientific), and 
qPCR was performed according to the manufacturer’s protocol 
with TaqMan hPSC Scorecard assay (Thermo Fisher Scientific). 
Data were analyzed with the online Scorecard software (Thermo 
Fisher Scientific).
Real-time PCR
Total RNA extraction was performed with the GenElute Mammalian 
Total RNA Kit (Sigma-Aldrich). cDNA was synthesized from 1 g 
of total RNA using SuperScript III First-Strand Synthesis SuperMix 
for qRT-PCR (Invitrogen) according to the manufacturer’s instruc-
tions. The qPCR for Sendai virus detection was performed using 
TaqMan Gene Expression Assays (Life Technologies). Quantitative 
RT-PCR was performed using SYBR Green PCR Master Mix (Applied 
Biosystems) on the 7500 Step OnePlus Real-Time PCR System 
(Applied Biosystems). Relative gene expression was determined by 
the 2−Ct method with normalization to GAPDH mRNA.
Repeat-primed PCR
The C9orf72 repeat expansion mutation was confirmed in both 
C9-ALS/FTD iPSCs and MNs by repeat-primed PCR (RP-PCR). 
First, the G4C2 hexanucleotide repeat was amplified using the 
forward primer C9orf72-PCR-F (6-FAM) CAAGGAGGGAAACAAC-
CGCAGCC and the reverse primer C9orf72-PCR-R GCAGGCAC-
CGCAACCGCAG. The PCR mix was prepared in a 25-l solution 
consisting of 100 ng of genomic DNA, 10× PCR amplification buf-
fer, 0.5 l of Taq DNA polymerase (Roche), 2.5 M forward primer, 
2.5 M reverse primer, 2 mM deoxyribonucleotide triphosphate 
(dNTP) (Amersham Biosciences), 50 mM MgSO4 (Invitrogen), 6 l 
of PCR enhancer solution (Invitrogen), and dH2O to the final vol-
ume. After a 5-min incubation at 94°C, the reactions were subjected 
to 28 cycles of 95°C for 30 s, 55°C for 30 s, 68°C for 60 s, followed by 
a 5-min extension at 68°C. The forward primer C9orf72_F_FAM_
bis (6-FAM)-AGTCGCTAGAGGCGAAAGC, the reverse primer 
C9orf72_R1_bis TACGCATCCCAGTTTGAGACGGGGGCCGG-
GGCCGGGGCCGGGG, and the second reverse primer C9orf72_
R2_bis TACGCATCCCAGTTTGAGACG were used for the 
amplification of the G4C2 hexanucleotide repeat. The RP-PCR assay 
was performed in a reaction volume of 25 l containing 100 ng of 
genomic DNA, 10× Expand long template buffer 2 (Roche), Expand 
long template enzyme mix (Roche), 2.5 M primer F, 2.5 M prim-
er R1, 2.5 M primer R2, 20 mM dNTPs (Amersham Biosciences), 
5 mM betaine (Sigma-Aldrich), and dH2O to the final volume. After 
a 10-min incubation at 98°C, the reactions were subjected to 10 cy-
cles of denaturation at 97°C for 35 s, 53°C for 2 min, 68°C for 2 min, 
followed by 25 cycles (+20 s per cycle) of 97°C for 35 s, 53°C for 2 
min, and 68°C for 2 min. This step was followed by a 10-min exten-
sion at 68°C. PCR products were incubated at 95°C for 3 min and 
cooled on ice followed by 5 l of each PCR product being added to 
18 l of formamide (Sigma-Aldrich) and 2 l of Genescan 500 Rox 
Size Standard (Applied Biosystems). Fragment length analysis was 
performed with GeneMapper software version 4.0 (Applied Biosystems) 
following electrophoresis on an automatic sequencer (DNA Analyzer; 
Applied Biosystems). A characteristic stutter amplification pattern 
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Southern blotting
Southern blots were performed as described previously (58). Briefly, 
genomic DNA was extracted using the Wizard Genomic DNA 
Purification Kit (Promega) and digested with the Xba I restriction 
enzyme (Promega). After electrophoresis for 6 hours at 100 V on a 
0.8% agarose gel, DNA was transferred to a positively charged 
nylon membrane (Roche) and then cross-linked by ultraviolet (UV) 
irradiation. Hybridization was performed with a digoxigenin (DIG)– 
labeled probe (Roche). The probe was detected with an anti-DIG 
antibody (Roche; 1:10,000) and visualized using CDP-Star substrate 
(Roche) and autoradiography film.
Neurite outgrowth assay
Time-lapse imaging of neurite outgrowth was performed using the 
IncuCyte Zoom system (Sartorius). sMNs were plated on 24-well 
plates at day 10 of the motor neuron differentiation at a density of 
~20,000 cells per well. A minimum of four bright-field images were 
taken per day using a 20× Plan Fluor objective [0.45 numerical 
aperture (NA), Nikon] from days 14 to 18. The lengths of neurites 
were automatically measured using the IncuCyte Zoom Neurotrack 
software module.
Electrophysiology
Whole-cell patch-clamp recordings from day 38 iPSC-derived 
motor neurons were performed at room temperature in artificial 
cerebrospinal fluid (aCSF) consisting of 140 mM NaCl, 5 mM KCl, 
2 mM CaCl2, 2 mM MgCl2, 10 mM Hepes, and 12 mM glucose 
(pH 7.4; ~300 mOsm). Borosilicate glass patch pipettes were pulled by a 
vertical PIP6 micropipette puller (HEKA Elektronik) and filled with 
an internal solution containing 120 mM K-gluconate, 20 mM KCl, 
1 mM MgCl2, 10 mM Hepes, 0.2 mM EGTA, 0.3 mM Na-GTP 
(guanosine triphosphate), 5 mM NaCl, and 4 mM Mg-ATP 
(adenosine triphosphate) (pH 7.3; ~290 mOsm). Motor neurons were 
visualized with an inverted Olympus IX73 microscope equipped 
with a 40× objective (0.60 NA, Ph2). Action potentials were record-
ed in current-clamp mode. Signals were acquired, filtered (at 2.8 kHz), 
and digitized (at 20 kHz) using an EPC10 USB amplifier and PatchMaster 
software (HEKA Elektronik). The liquid junction potential of 13.8 mV 
was corrected offline. Action potentials were detected using Stimfit 
software.
Digital droplet PCR
The QX200 Droplet Digital PCR (ddPCR) system (Bio-Rad) was 
used to provide absolute measurements of C9orf72 mRNA, as well 
as each of the V1, V2, and V3 transcript variants. Total RNA was 
extracted with the RNeasy Mini Kit (Qiagen) following the manu-
facturer’s instructions. The cDNA was obtained using the SuperScript III 
First-Strand Synthesis System for RT-PCR kit (Thermo Fisher Sci-
entific) according to the manufacturer’s instructions. Digital droplet 
PCR was performed following guidelines from Bio-Rad. Briefly, 
each ddPCR mix was prepared in a 22-l solution consisting of 2× 
ddPCR Supermix for probes (without deoxyuridine triphosphates), 
20× FAM TaqMan probe, 20× Hex TaqMan probe, 4 l of diluted 
cDNA (1:10), and 4.8 l of nuclease-free dH2O (Thermo Fisher 
Scientific). Droplets were generated in the QX200 Droplet Generator 
and transferred to a standard 96-well PCR plate that was heat-sealed 
using foil sheets (Pierceable Foil Heat Seal, Bio-Rad) and a PX1 
PCR plate sealer. The droplets were amplified using a Bio-Rad 
T100 thermal cycler starting with 10-min enzyme activation 
at 95°C, followed by 40 cycles of 95°C, 30 s and 60°C, 1 min and a 
final hold at 98°C for 10 min (2°C/s ramp rate). The fluorescence 
of each thermal cycled droplet was measured using the QX200 
Droplet Reader (Bio-Rad), and the results were analyzed with 
QuantaSoft software (Bio-Rad) after threshold setting on fluores-
cence of negative controls. The number of positive and negative 
droplets was used to calculate the concentration (cDNA copies/l of 
the final 1× ddPCR) of the targets and their Poisson-based 95% 
confidence intervals. A reference gene, SCLY, was included to in-
crease the accuracy of the relative gene expression. Graphs show 
relative expression levels. The V1 (6-FAM-TAA TGT GAC-ZEN-
AGT TGG AAT GC-IBFQ), V2 (6-FAM-CGG AGC ATT-ZEN- 
GG ATA ATG TGA CAG TTG G-IBFQ), V3 (6-FAM-TAA TGT 
GAC-ZEN-AGT TGG AAT GC-IBFQ), and Vall (6-FAM-ACA 
GAG AGA-ZEN-ATG GAA GAT CAG GGTC AGA-IBFQ) probes 
were used in this experiment (6-FAM, 6-carboxyfluorescein; 
ZEN, internal quencher; IBFQ, Iowa Black dark fluorescence 
quencher).
Analysis of C9orf72 protein levels
Cell pellets were lysed by resuspension in radioimmunoprecipitation 
assay (RIPA) buffer [50 mM tris-HCl (pH 7.5), 150 mM NaCl, 1% 
NP-40, 0.5% Na-deoxycholic acid, 0.5% SDS] supplemented with 
cOmplete EDTA-free Protease Inhibitor Cocktail (Sigma-Aldrich). 
The samples were centrifuged at 14,000  rpm for 20 min, and the 
supernatant was transferred to a prechilled tube. Total protein con-
centrations were quantified using the Micro BCA Protein Assay Kit 
(Thermo Fisher Scientific) according to the manufacturer’s instruc-
tions. Equal amounts of proteins were boiled at 95°C with 5× reduc-
ing sample buffer (Thermo Fisher Scientific) and separated by 
SDS–polyacrylamide gel electrophoresis (SDS-PAGE). After elec-
trophoresis, the proteins were transferred to a polyvinylidene diflu-
oride (PVDF) membrane (Trans-Blot Turbo Mini 0.2 m PVDF, 
Bio-Rad) using the Trans-Blot Turbo Transfer System (Bio-Rad, 
Mixed MW program, 25 V, 1.3 A, 7 min). The membranes were 
blocked with 5% nonfat dry milk diluted in tris buffer saline solu-
tion with Tween [TBS-T; 1 M tris-HCl (pH 7.5), 150 mM NaCl, 
0.1% Tween 20] for 1 hour at room temperature followed by over-
night incubation at 4°C with anti-C9orf72 primary antibody 
(table S7) diluted in TBS-T. For the loading control signals, the 
membranes were subsequently incubated for 2 hours at room tem-
perature with anti-Calnexin primary antibody (table S7) diluted 
in TBS-T. Following incubation with the primary antibodies, mem-
branes were washed three times with TBS-T and incubated for 
1 hour at room temperature with secondary antibodies coupled to 
horseradish peroxidase [anti-mouse or anti-rabbit, 1:5000, Agilent 
Technologies (Dako)]. After three washes with TBS-T and one 
wash with TBS, chemiluminescence signals were generated by ECL 
Western Blotting Substrate (Thermo Fisher Scientific) or SuperSignal 
West Femto Maximum Sensitivity Substrate (Thermo Fisher Scien-
tific) and detected with the ImageQuant LAS 4000 Biomolecular 
Imager (GE Healthcare Life Sciences). Band intensities were quan-
tified using ImageQuant TL version 7.0 software (GE Healthcare 
Life Sciences) and normalized to the Calnexin loading control.
Enzyme-linked immunosorbent assay
Poly-GP and poly-GA levels in control and C9orf72-derived sMN 
lysates were measured using a sandwich immunoassay that uses 









Fumagalli et al., Sci. Adv. 2021; 7 : eabg3013     9 April 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
13 of 20
technology. Lysates were diluted in assay diluent (1% Blocker-A/
PBST), and equal amounts of protein for all samples were tested for 
poly-GP. The assay uses an affinity-purified goat polyclonal anti-
body to poly-GP (Biogen-3746, 1 g ml−1) as capture, and mouse 
monoclonal poly-GP antibody (Biogen-2P8H9.1.1, 0.5 g ml−1) 
along with a SULFO-tag anti-mouse secondary antibody (1 g ml−1), 
to detect captured poly-GP. Similarly, lysates were diluted in assay 
diluent (1% Blocker-A/PBST) and equal amounts of protein for all 
samples were tested for poly-GA using an affinity-purified goat 
polyclonal antibody to poly-GA (Biogen-3682, 1 g ml−1) as capture, 
and mouse monoclonal to poly-GA antibody (Biogen-2P36E2.1.1, 
1 g ml−1) along with a SULFO-tag anti-mouse secondary antibody 
(1 g ml−1). Each sample was tested in duplicate wells, sample 
volume permitting, using 50 l per well. Each assay plate contained 
the same control samples (serial dilutions of iPSC motor neuron cell 
lysates derived from a C9orf72 mutation carrier and a noncarrier, 
and serial dilutions of synthetic GP8 or GA8). The reported response 
values correspond to intensity of emitted light upon electrochemical 
stimulation of the assay plate using MSD Quickplex SQ120 after 
subtraction of the background signal in wells containing only as-
say buffer.
Cell viability assay
Cell viability after DPR treatment was measured using DRAQ7 
(Abcam) far-red fluorescent DNA dye, a cell impermeable agent 
that only stains the nuclei in cells with a compromised cell mem-
brane (i.e., that are in the process of dying). DRAQ7 was added to 
each well at a concentration of 3 M together with Hoechst 33342 
(1:1000, Thermo Fisher Scientific) and incubated for 20 min at 
37°C. Cells were then washed once with Dulbecco’s modified 
Eagle’s medium (DMEM)/F12 and fixed with 4% paraformaldehyde 
in PBS for 20 min. For this experiment, motor neurons were cul-
tured in a CellCarrier 96-well plate (PerkinElmer). Motor neurons 
were treated with the respective synthetic peptides (PR20, GR20, and 
GP20; Pepscan), and the analysis was performed 16 hours after 
treatment. Untreated cells were used as the control group for PR20 
and GR20. To allow the uncharged GP20 peptide to pass the cellular 
membrane, cells were treated with streptolysin O (SLO; 15 ng ml−1, 
Sigma-Aldrich) diluted in Hanks’ balanced salt solution (HBSS) 
(without Ca2+, Gibco) containing 30 mM Hepes (Sigma-Aldrich) 
for 15 min at 37°C. In this case, cells treated with SLO without GP20 
peptide were used as untreated controls. Images were acquired 
using the Operetta CLS High Content Screening (HCS) System 
(PerkinElmer, UK) using a 20× air objective lens (0.4 NA, correc-
tion collar). Seventy-seven fields of view were acquired per well. 
Images were analyzed using Harmony software (PhenoLOGIC, 
PerkinElmer).
Visualization and analysis of cargo transport in human 
motor neurons
Motor neuron cultures were stained with MitoTracker Red (50 nM, 
Invitrogen) or SYTO RNASelect Green fluorescent (500 nM, Invitrogen) 
for 20 min at 37°C, according to the manufacturer’s instructions. 
Control sMNs were treated with the respective synthetic peptides 
for 16 or 72 hours before analysis of cargo transport, as described 
for the cell viability assay. Live cell imaging was performed using an 
inverted Zeiss Axiovert 200M microscope (Carl Zeiss) with a 40× 
water immersion lens (1.2 NA, C-Apochromat). During the record-
ing, the cells were perfused with Hepes solution (10 mM Hepes, 
148 mM NaCl, 5 mM KCl, 0.1 mM MgCl2, 10 mM glucose, and 
2 mM CaCl2) and maintained at a temperature of 36 ± 0.5°C using 
a gravity-fed and heated perfusion system (custom built). A TILL 
Poly V light source (Till Photonics, Graefelfing, Germany) was used 
to excite MitoTracker (540 nm) and RNASelect (475 nm), and 200 images 
at 1 Hz were recorded by a cooled charge-coupled device (CCD) 
camera (PCO sensicam-QE) using TILL VisION (TILL Photonics) 
software. All image analysis was performed in Igor Pro (Wavemetrics, 
Portland, USA) using custom-written routines (59). Neurites with at least 
one moving organelle were considered for the analysis. Kymographs 
were generated for each neuronal process to distinguish stationary 
mitochondria (visible as vertical lines) and moving mitochondria 
(visible as diagonal lines). The numbers of stationary and moving 
mitochondria were calculated by counting straight and diagonal 
lines on the kymographs.
When assessing pausing of motile mitochondria in sMNs, 
movies were stabilized if required using the ImageJ plugin Stackreg. 
Kymographs were generated along neurites, and all mitochondrial 
movements were examined for pausing. Pauses within or at the end 
of runs were scored only if the stationary event exceeded 3 s (>3 
frames). Blinded analysis was carried out to avoid introducing 
unconscious bias.
To determine the directionality of transport, cells were sparsely 
transduced with lentivirus expressing mitoDsRed2 at day 16 of the 
sMN differentiation using a multiplicity of infection (MOI) of 0.5, 
optimized to visualize one to two labeled cells per field of view. 
Imaging of mitochondrial axonal transport was performed at day 38 
of sMN differentiation with a 63× oil immersion lens [Plan-Apochrat 
1.40 NA (DIC M27) objective, Carl Zeiss] using an Axio Observer 
Z1 inverted motorized microscope (Carl Zeiss) equipped with an 
Cy3 FL filter set (Carl Zeiss), Zen 2011 z-stack, time-lapse and 
definite-focus modules (Carl Zeiss), and an S1 Environmental System 
incubation chamber (Carl Zeiss) maintained at 37°C and 5% CO2. 
Medium was changed 30 min before imaging to phenol red–free 
Neurobasal medium supplemented with 1× GlutaMAX. Mitochondrial 
movements were recorded for 5 min using a 0.2-Hz capture of a 
100-m stretch of neurites and a small z-stack. At least four neurites 
were imaged per cell line per differentiation. sMN genotypes 
were counterbalanced and interleaved between experimental runs. 
Maximum intensity projections were computed in Fiji. Kymographs 
were generated and analyzed using KymoToolBox in Fiji to deter-
mine the numbers of stationary (≤0.1 m/s) versus motile mito-
chondria and the predominant directionality of movement [either 
away from (anterograde) or toward (retrograde) the soma].
Drosophila husbandry and strains
Flies were fed with Iberian food [5.5% (w/v) glucose, 5% (w/v) 
baker’s yeast, 3.5% (w/v) organic flour, 0.75% (w/v) agar, 16.4 mM 
methyl-4-hydroxybenzoate, 0.004% (v/v) propionic acid] and 
maintained at 25°C on a 12-hour-light, 12-hour-dark cycle at 
50 ± 5% humidity. The following strains were used: yw [control 
(Bullock laboratory stocks)]; w1118 [control (Bullock laboratory 
stocks)]; GMR-Gal4 UAS-GR36/CyO and GMR-Gal4 UAS-PR36/
CyO (9); FRT G13 Khc27/CyO and b1 pr1 Khc8/CyO DGY (Khcnull 
alleles) (60); DhcSTOP/TM6B [Dhcnull allele (contains a CRISPR- 
induced out-of-frame indel that causes a premature stop at codon 
169) (wild-type protein has 4638 codons) (see below)]; dpr-Gal4; 
UAS-mito::GFP/CyO-TM6B (61); and UAS-GA36, UAS-GA100, 









Fumagalli et al., Sci. Adv. 2021; 7 : eabg3013     9 April 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
14 of 20
experiment in fig. S16C, the Khc27 allele was outcrossed into a w1118 
background for seven generations before rebalancing using a yw; 
Pin/CyO stock. The control stock for this experiment was made us-
ing the Khc+/CyO siblings from the rebalancing cross. The Dhcnull 
allele was generated as described (62) by injecting embryos of the 
nos-cas9 strain with a pCFD3 plasmid expressing a guide RNA 
(gRNA) with the following target site: CGCGGCCTGGTCGT-
GGAGG. The mutation was then outcrossed to a w1118 back-
ground for seven generations before balancing with a yw;; MKRS/
TM6B stock.
Assessment of mitochondrial trafficking in the Drosophila 
marginal wing nerve
dpr-Gal4; UAS-mito::GFP/CyO-TM6B males were crossed to virgin 
females of the following genotypes: yw (control), UAS-GA36, UAS-
GA100, UAS-GR36, UAS-GR100, UAS-PR36, and UAS-PR100. Recently 
eclosed male dpr-Gal4, UAS-mito::GFP offspring with and without 
UAS-‘DPR’ transgenes were collected and aged for ~48 hours. Male 
flies were used for all phenotypic analysis to control for any sex- 
specific phenotypic effects. Flies were anesthetized with CO2 (0.8 bar) 
for 5 min and then mounted on No.1 coverslips with their wings 
gently spread out in a thin layer of 10S Voltaleff halocarbon oil 
(VWR), as described (36). Movies were typically acquired from 
both wings at 0.5 Hz for 180 s using a single-channel acquisition at 
488 nm and processed and analyzed in Fiji using the CellCounter 
and MTrackJ plugins. Movies were acquired on a PerkinElmer 
Spinning Disk confocal using a 60× oil-immersion objective (PlanApo, 
1.4 NA) and an Olympus IX71 microscope. Movies were oriented 
so that cell bodies (retrograde direction) were on the left and axon 
termini (anterograde direction) were on the right. Movies were 
stabilized using StackReg (Rigid body) and straightened using the 
in-built Fiji Straighten tool before being cropped to display 50 m 
of the wing nerve. Processed movies were analyzed blind to the 
genotype. Mitochondria number was defined as average number 
of mitochondria when counted at the 1st, 46th, and 91st frames 
(counted with the CellCounter plugin). Mitochondrial movements 
were tracked using the MTrackJ plugin in Fiji. Movements were 
considered a transport event if the total displacement exceeded 2 m. 
A transient stationary period of a motile mitochondrion was scored 
as a “pause” if it lasted ≥2 frames (≥4 s). Results were exported 
from CellCounter and MTrackJ into Excel and plotted in Prism 8 
(GraphPad).
Assessment of Drosophila viability and eye defects
Male GMR-Gal4 UAS-GR36 or GMR-Gal4 UAS-PR36 flies were 
mated with females with Khc or Dhc null alleles or yw controls to study 
the effects of motor gene dosage on DPR toxicity. Although GMR-Gal4 
is predominantly expressed in the eye, its ability to cause lethality in 
combination with UAS-GR36 (9) indicates that it has some activity 
in other tissues (the eye is not required for survival to adulthood). 
Each type of cross was set up in triplicate, with at least two egg lays 
(of 3 days each) analyzed per cross. Adult offspring were collected 
and aged to 4 to 6 days after eclosion before analysis. For all crosses 
that produced a sufficient number of offspring (>15 internal control 
animals that did not inherit the GMR-Gal4 UAS-GR36 chromo-
some), the number of male flies of different genotypes that inherited 
the GMR-Gal4 UAS-GR36 chromosome was counted. These values 
were plotted as a percentage of the expected number of offspring 
for each genotype assuming no lethality, based on the number of 
control offspring that did not inherit the UAS-GR36 chromosome. 
To account for the contribution of genetic background, both an 
outcrossed Khc27 line and an independent null allele of Khc were 
also assessed for lethality (see the “Drosophila husbandry and 
strains” section).
For analysis of eye defects, a single eye per GMR-Gal4 UAS-PR36 
male was scored using a qualitative scale of eye disruption (no, 
mild, moderate, and severe; table S4). Necrotic patches were not 
classed as pigmentation. See fig. S16A for example images for each 
category. All eye scoring was carried out blind of the genotypes. In 
control experiments, we confirmed that decreased motor gene 
dosage does not affect survival or eye morphology in the absence of 
GR36 or PR36 expression (table S4).
Drosophila eye imaging
Images exemplifying the different classes of eye phenotype were 
acquired using a Nikon “Multiphot” macrophotography setup, with a 6× 
Macro-Nikkor 35-mm lens and a Sony a6300 “mirrorless” 24-megapixel 
camera, followed by processing in Adobe Photoshop CS6.
Mouse procedures and husbandry
For spinal cord dissection, C57BL/6 mice (The Jackson Laboratory) 
were anesthetized with isoflurane and transcardially perfused with 
0.9% saline. Isolated spinal cords were used immediately for sample 
preparation. All mouse procedures and husbandry were performed 
in accordance with Institutional Animal Care and Use Committee 
guidelines and approved by the Stanford Administrative Panel on 
Animal Care.
PR30 protein precipitation
Mouse spinal cords were disintegrated in PBS buffer with Halt 
Protease inhibitor (Thermo Fisher Scientific) with a Dounce homog-
enizer. The cell suspension was subsequently lysed on ice using a 
probe sonicator (Branson Sonifier 250, VWR Scientific). The solu-
ble lysate was cleared from the insoluble fraction by centrifugation 
for 15 min at 10,000 rpm (11,292g) at 4°C (Eppendorf 5427 R). The 
supernatant was retrieved, and the procedure was repeated until 
no pellet was visible after centrifugation. The protein concentration 
was measured using the Micro BCA assay (Thermo Fisher Scientific). 
PR30 (Pepscan) was added to a final concentration of 50 M to 
0.5 mg of soluble lysate in a total volume of 400 l, and samples 
were incubated for 15 min. The volume of the samples was 
increased to 1.5 ml with PBS before gently spinning down the PR 
droplets at 4000 rpm (3220g) for 5 min (Eppendorf 5810 R). Eppendorf 
tubes with phase-separated samples were dispensed in 50 ml Falcon 
tubes and spun down in a swinging-bucket centrifuge. Pellets were 
subsequently washed with 1 ml of PBS and vortexed before spinning 
down again. Washing steps were repeated three times. The resulting 
pellets were processed for liquid chromatography–tandem mass 
spectrometry (LC-MS/MS).
For cross-linked samples (see table S5), after incubation with 
PR30, paraformaldehyde (Sigma-Aldrich) was added to a final 
concentration of 0.5% for 5 min. Five hundred microliters of 2 M 
glycine (Sigma-Aldrich) was then added for 5 min to quench 
paraformaldehyde. Samples were subsequently treated the same as 
uncross-linked samples. Samples for analysis by SDS-PAGE and 
silver staining were processed identically, with silver staining per-
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Proteomics sample preparation and LC-MS/MS analysis
Pellets were redissolved in 8 M urea in PBS and solubilized by 
sonication, with a total sample volume of 1.5 ml. Proteins in each 
sample were reduced with 5 mM dithiothreitol (DTT) (30-min 
incubation at 55°C) and alkylated by addition of 10 mM iodoacetamide 
for 15 min at room temperature in the dark. Samples were further 
diluted to give a final urea concentration of 2 M, and proteins 
were digested with trypsin (1:100, w/w) (Promega) overnight at 
37°C. Peptides were purified on Omix C18 tips (Agilent) and dried 
and redissolved in 25 ml of solvent A [0.1% trifluoroacetic acid 
(TFA) in dH2O/acetonitrile (98:2, v/v)]. Ten milliliters of this 
material was injected for LC-MS/MS analysis on the Ultimate 3000 
RSLCnano System (Dionex, Thermo Fisher Scientific) in-line 
connected to a Q Exactive HF mass spectrometer fitted with a 
Nanospray Flex Ion source (Thermo Fisher Scientific). Trapping 
was performed at 10 ml/min for 4 min in solvent A (on a reversed- 
phase column produced in-house, 100-mm inside diameter (ID) × 
20 mm, 5-mm beads C18 Reprosil-Pur, Dr. Maisch). The sample 
was then loaded on a 40-cm column (produced in-house, 75-mm 
ID × 400 mm, 1.9-mm beads C18 Reprosil-HD, Dr. Maisch). 
Peptides were eluted using an increase in solvent B [0.1% formic acid 
in dH2O/acetonitrile (2:8, v/v)] in linear gradients from 2 to 3% over 
100 min, then from 30 to 56% over 40 min, and from 56 to 99% from 
5 min (all with a constant flow rate of 250 nl/min). The mass 
spectrometer was operated in data-dependent mode with automatic 
switching between MS and MS/MS acquisition for the 16 ion peaks 
per spectrum with the highest abundance. Full-scan MS spectra 
[375 to 1500 mass/charge ratio (m/z)] were acquired at a resolution of 
60,000 after accumulation to a target value of 3,000,000 (maximum fill 
time, 60 ms). The 16 most intense ions above a threshold value of 
22,000 were isolated (window of 1.5 Th) for fragmentation at a nor-
malized collision energy of 32% after filling the trap at a target value of 
100,000 for a maximum of 45 ms. The S-lens RF level was set at 55, and 
precursor ions with single and unassigned charge states were excluded.
Data analysis was performed using MaxQuant software (version 
1.5.3.30) with the Andromeda search engine with default search 
settings (including a 1% false discovery rate at both the peptide and 
protein level). Spectra were searched against the mouse proteins in 
the UniProt/Swiss-Prot database (database release version of 
April 2016 containing 20,103 mouse protein sequences, www.uniprot.
org). For precursor and fragment ions, mass tolerances were set to 
4.5 and 20 parts per million, respectively, during the main search. 
Enzyme specificity was set as C-terminal to arginine and lysine, 
with cleavage at proline bonds also permitted, with a maximum of 
three missed cleavages. Variable modifications were set to acetyla-
tion of protein N termini and oxidation of methionine residues. 
Only proteins with at least one unique or razor peptide were re-
tained, which lead to identification of 1811 mouse proteins. Pro-
teins were quantified using the MaxLFQ algorithm integrated in the 
MaxQuant software (63). Quantification required a minimum ratio 
count of two unique or razor peptides. Perseus software (version 
1.5.3.0) was used for further data analysis after loading the MaxQuant 
protein groups file. Proteins identified only by site and reverse database 
hits were removed. Missing values were produced by imputation 
from a normal distribution around the detection limit.
Coimmunoprecipitation
Motor neurons were treated with 10 M of HA-labeled DPR 
peptides (PR20, GR20, and GP20; Pepscan) for 3 hours. Subsequently, 
medium was removed and washed once with ice-cold DPBS (Sigma- 
Aldrich). Motor neurons were gently scraped off the dish and 
centrifuged for 5 min, 400g at 4°C. Cell pellets were cross-linked 
using 1% paraformaldehyde (Sigma-Aldrich) in DPBS and incubat-
ed for 10 min at room temperature. The cross-linking reaction was 
stopped with 1/10 volume of 1.25 M glycine (pH 8) (Thermo Fisher 
Scientific). Cross-linked cell pellets were washed three times with 
ice-cold DPBS followed by lysis or snap freezing and storage at 
−80°C. Cell pellets were lysed in ice-cold lysis buffer [150 mM 
NaCl, 25 mM tris, 1 mM EDTA, 1% NP-40, and 5% glycerol (pH 7.4)] 
supplemented with complete EDTA-free protease inhibitor cocktail 
(Roche Diagnostics). Cell debris was removed via centrifugation, 
and supernatants were mixed with Pierce anti-HA magnetic beads 
(Thermo Fisher Scientific). The mixture was incubated for 1 hour at 
room temperature with agitation. Afterward, the beads were washed 
three times with lysis buffer. The HA-tagged dipeptides and associ-
ated material were eluted using the manufacturer’s buffers.
For immunoblot analysis, samples were resolved on 4 to 20% 
mini-protean TGX stain-free gels (Bio-Rad) and transferred to 
nitrocellulose membrane (Bio-Rad). Membrane was blocked with 
5% nonfat milk (Bio-Rad) in TBS-T for 2 hours at room tempera-
ture and incubated with primary antibodies overnight at 4°C (table 
S7). The next day, the membranes were washed three times with 
TBS-T and incubated for 1 hour with secondary Trueblot antibodies 
(Rockland). Proteins were detected by enhanced chemiluminescence 
reagents (Thermo Fisher Scientific) and detected with the ImageQuant 
LAS 4000 Biomolecular Imager (GE Healthcare Life Sciences).
Proximity ligation assay
Duolink PLA (Sigma-Aldrich) was performed according to the 
manufacturer’s instructions. Briefly, samples were fixed with 4% 
paraformaldehyde in PBS for 20 min, rinsed three times, and incu-
bated for 1 hour at room temperature in PBS containing 0.2% 
Triton X-100 and 5% donkey serum. Cells were incubated overnight 
at 4°C in 2% donkey serum containing the primary antibodies. 
After washing twice in 1× Duolink wash buffer A for 5 min, cells 
were incubated with secondary antibodies conjugated with oligo-
nucleotides (PLA probes anti-mouse MINUS and anti-rabbit PLUS) 
for 1 hour in a preheated humidity chamber at 37°C. See table S7 for 
details of antibodies. The samples were washed twice in Duolink 
washing buffer A for 5 min, and then the Duolink ligation solution 
was applied to the samples for 30 min in a preheated humidity 
chamber at 37°C. Cells were rinsed twice with Duolink washing 
buffer A for 5 min and the Duolink amplification-polymerase solu-
tion applied to the samples in a dark, preheated humidity chamber 
for 100 min at 37°C. The samples were then washed twice in 1× 
Duolink washing buffer B for 10 min at room temperature followed 
by a 1-min wash with 0.01× Duolink washing buffer B. The cells 
were stained with phalloidin for 1 hour in PBS with 2% donkey 
serum, rinsed three times with PBS, and incubated for 20 min in PBS/
DAPI (NucBlue Live ReadyProbes Reagent, Invitrogen). Coverslips 
were mounted using ProLong Gold antifade reagent (Invitrogen), 
and confocal images were obtained using a Leica SP8 DMI8 con-
focal microscope. PLA signals were recognized as red fluores-
cent spots.
Immunofluorescence of postmortem brains
To assess colocalization between GR aggregates and KIF5B in C9-
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cord tissue previously collected in the UZ Leuven brain biobank in 
accordance with the ethics review board upon written informed 
consent. In this study, five C9orf72 expansion carriers were used for 
the analysis in the frontal cortex of the brain and one C9orf72 
expansion carrier was used for the analysis in the spinal cord (for 
clinical information, see table S1). ALS patients without the C9orf72 
expansion were chosen as controls (table S1). Frozen tissue sections 
of 7 to 8 m thickness were washed with Bond Wash Solution (Leica 
Biosystems) for 15 min at room temperature and stained overnight 
with the primary antibodies at 4°C (table S7). The following day, 
slides were washed three times with Bond Wash Solution before the 
secondary antibodies (table S7) were added for 90 min at room tem-
perature. After three washing steps with Bond Wash Solution, the 
slices were mounted using ProLong Gold antifade reagent with 
DAPI (Invitrogen). Confocal images were obtained using a Leica 
SP8 DMI8 confocal microscope. Images were analyzed, formatted, 
and quantified with ImageJ software.
Proteins and DPRs
Full-length human dynein with a SNAPf-tag on dynein heavy chain 
was expressed in Spodoptera frugiperda Sf9 cells and purified and 
labeled with fluorophores as described previously (64). A SNAPf 
fusion of mouse BICD2N (not labeled with a fluorophore) was also 
produced from Sf9 cells using published methods (64). Native 
dynactin was purified from pig brain by SP-Sepharose–based puri-
fication as described (64).
Active kinesin-1 (1–560 truncation of KIF5B containing the 
motor domain and dimerization stalk) was purified from Rosetta 2 
Escherichia coli (DE3, Novagen), transformed with the pET17-
K560-GFP-His plasmid (43), and cultured at 37°C. Expression was 
induced with 0.1 mM isopropyl--d-thiogalactopyranoside (IPTG), 
with cells harvested 14 to 18 hours later by centrifugation for 20 min 
at 3000g (JLA 8.1 rotor) and resuspended in buffer A [50 mM 
Na-phosphate buffer (pH 8), 1 mM MgCl2, 250 mM NaCl, and 
1 mM phenylmethylsulfonyl fluoride (PMSF)]. Following lysis by 
sonication, insoluble material was removed by centrifugation for 
35 min at 27,000g (70 Ti rotor). Initial purification was carried out 
by Ni2+-affinity chromatography (HisTrap FF 5 ml, GE Healthcare) 
and elution with 50 mM Na-phosphate buffer, 1 mM MgCl2, 250 mM 
NaCl, 250 mM imidazole, 50 mM Mg-ATP, and 1 mM PMSF 
(pH 7.2). Protein was concentrated using Amicon 100-kDa 15-ml 
tubes at 4°C (4000g spin) and washed in buffer A. Further purifica-
tion was achieved with a microtubule pull-down and release pro-
cedure, which enriches for the intact, active motor domain over 
degradation products (65). The protein sample was incubated with 
taxol-stabilized microtubules (15 mg ml−1) and 1 mM AMP-PNP 
(Sigma-Aldrich), and the mixture was overlaid on a glycerol cushion 
{BRB80 [80 mM Pipes (pH 6.9), 1 mM EGTA, 1 mM MgCl2], 20 M 
taxol, and 60% glycerol (v/v)}. Centrifugation was performed with a 
TLA 100 rotor at 317,000g for 10 min. The pellet was resuspended 
in BRB80 with 50 mM KCl and 5 mM ATP and incubated for 
10 min to trigger release of microtubule-bound motors. Centrifugation 
at 317,000g for 10 min yielded supernatant containing the released 
active motors, which were snap-frozen in small aliquots in 20% 
glycerol (v/v) and stored at −80°C.
Porcine tubulin conjugated to fluorophores or biotin was purchased 
from Cytoskeleton Inc. High-performance liquid chromatography– 
purified DPRs were purchased from Pepscan and were either labeled 
with a single Cy5 dye at the N terminus during synthesis or labeled 
non–site-specifically in-house using Alexa Fluor 488 Protein Label-
ing Kit (Thermo Fisher Scientific) using published methods (66).
Single-molecule motility assays
Biotinylated and fluorescently labeled porcine microtubules stabilized 
with taxol and GMP-CPP (guanosine-5′-[(,)-methyleno]triphosphate), 
PEG (polyethylene glycol)–biotin passivated glass surfaces, and 
motility chambers were prepared as described previously (64). For 
assays with TMR-dynein, microtubules were polymerized in the pres-
ence of HiLyte488- tubulin, with the exception of the experiments doc-
umented in Figs. 5E and 6  (E  to G) and fig. S20 (B and C) and in 
which HiLyte647-tubulin was used for conditions in the presence 
of Alexa Fluor 488–PR30. Tetramethyl rhodamine isothiocyanate 
(TRITC)–tubulin was used for KIF5B::GFP assays. Stabilized mi-
crotubules were immobilized on the biotinylated glass surface in the 
motility chamber for 30 s and subsequently washed once with motility 
buffer (30 mM Hepes, 5 mM MgSO4, 1 mM EGTA, 1 mM DTT). 
For this and subsequent steps, the pH of motility buffer was adjusted 
to 7.0 for KIF5B assays (kinesin motility buffer) and 7.3 for dynein 
assays (dynein motility buffer), as these conditions were optimal for 
movement of the respective motors.
KIF5B::GFP dimers (96 nM) were stored on ice before motility 
assays in kinesin motility buffer. For dynein assays, 138 nM TMR-
dynein dimers, 585 nM dynactin, and 1.9 M BICD2N dimers 
(molar ratio, 1:4:14) were mixed on ice for 5 to 10 min in dynein 
motility buffer. An independent assembly of dynein, dynactin, and 
BICD2N was used for each dynein assay chamber. KIF5B::GFP 
solutions were diluted 1:20 into kinesin motility buffer in the pres-
ence or absence of DPRs at the final concentrations indicated in 
Results. Dynein, dynactin, and BICD2N assembly mixtures were 
diluted 133-fold (with the exception of the complexes in Fig. 5C and 
fig. S21B, which were diluted 800-fold) in dynein motility buffer in 
the presence and absence of DPRs. Both final motility buffers also 
contained 25 mM KCl, -casein (1 mg ml−1), 5 mM MgATP, and an 
oxygen scavenging system (1.25 M glucose oxidase, 140 nM cata-
lase, 71 mM 2-mercaptoethanol, and 25 mM glucose) to minimize 
photobleaching. Diluted protein samples were promptly injected 
into imaging chambers.
Imaging was performed at room temperature (23 ± 1°C) with a 
Nikon TIRF microscope system controlled with Micro-Manager 
and equipped with a 100× oil objective (Nikon APO TIRF, 1.49 NA), 
as well as with Coherent Sapphire 488 nm (150 mW), Coherent 
Sapphire 561 nm (150 mW), and Coherent CUBE 641 nm (100 mW) 
lasers. Images were acquired with an iXonEM+ DU-897E EMCCD 
(electron multiplying charged coupled device) camera (Andor), which 
gave pixel dimensions of 105 nm by 105 nm. Different channels were 
imaged sequentially through automated switching of emission filters 
[GFP, Cy3, and Cy5 (Chroma Technology Corp.)]. For each cham-
ber, at least two dual-color acquisitions of 300 frames were made 
at the maximum achievable frame rate (~2 frames s−1) and 100-ms 
exposure per frame. Three chambers were imaged for every experi-
mental condition with the exception of 1 M PR30 in Fig. 5D and 
fig. S20A, where one chamber was imaged.
Kymographs were generated and manually analyzed using Fiji. 
Microtubule position was determined by the fluorescent tubulin 
signal or a projection of motor or DPR signal over the duration of 
the movie. From each chamber, typically 10 microtubules were 
selected for analysis across two movies (five microtubules per 
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15 microtubules were selected across three movies when assaying 
PR30 addition. Microtubules were chosen before visualizing the 
motile properties of associated motor complexes or pattern of DPR 
association. Preference was given to those microtubules that were 
relatively long and well separated from others in the field of view. 
Subsequent analysis of kymographs was carried out blind to the 
identity of the samples, with the exception of the experiments doc-
umented in Fig. 5 (D and E) and fig. S20. Blinding was not possible 
in these cases because either the magnitude of the effects on mo-
tility made it clear from which conditions the kymographs were 
derived or the batch of kymographs for analysis contained a single 
condition.
Interactions of fluorescently labeled motors with microtubules 
were operationally considered as binding events if they were ≥2 s 
(4 frames) in duration. As described previously (64), some processive 
complexes changed velocity within a run, which necessitated the 
calculation of velocities of individual constant-velocity segments. 
Run lengths were calculated from the total displacement of contin-
uous movements of complexes, irrespective of changes in velocity. 
Pauses within or at the end of runs were scored only if the stationary 
event exceeded 1.5 s (≥3 frames). For Fig. 5C, background signal 
was quantified by generating kymographs from randomly selected 
microtubule-free regions of the coverslip of lengths equal to the 
median microtubule length of those used for analysis. Although 
kymographs displayed in Fig. 5A had background subtracted in Fiji 
with a rolling ball radius of 100 pixels for illustrative purposes, the 
raw data were used for all quantitative analysis.
Quantification of peptide binding to microtubules in vitro
To quantify microtubule binding by Cy5-labeled DPRs to micro-
tubules with or without C-terminal tubulin tails, TRITC-labeled 
microtubules were first polymerized as described above. Microtubules 
resuspended in BRB80 with 20 M taxol were treated with a 1:50 (w/w) 
ratio of subtilisin (Sigma-Aldrich) to tubulin, or a buffer only con-
trol, for ~16 hours. Digestion was quenched with 5 mM PMSF and 
confirmed by gel electrophoresis and Coomassie staining. Micro-
tubules were then pelleted, washed, and resuspended in fresh BRB80 
with taxol before application to imaging chambers. Cy5-labeled 
DPRs in kinesin motility buffer were added to the chambers to a 
final concentration of 10 M. For analysis, five microtubules were 
selected randomly from three images acquired from two indepen-
dent chamber preparations. Mean Cy5 fluorescent intensity was 
then calculated using Fiji. Background signal was first subtracted 
with a rolling ball radius of 50 pixels to generate uniform fluores-
cent intensity across the region. Enrichment of fluorescence on 
microtubules was calculated by subtracting mean background in-
tensity from microtubule-associated intensity. Background intensity 
was calculated from five lines per image equivalent to the median 
length of microtubules assessed, which were positioned in microtubule- 
free areas close to the selected microtubules.
Analysis of motor pausing and detachment with  
PR30-decorated microtubules
Single-molecule motility data for KIF5B and dynein were acquired 
as described above. Additional analysis of the colocalization of 
pause and detachment sites for each motor with intense PR30 punc-
ta was carried out in Fiji. Co-incidence was scored if there was at 
least a 2-pixel overlap between the PR30 signal and signal from the 
incoming motor complex. For the simulated control, randomized 
binding patterns of PR30 foci were generated by overlaying existing 
kymographs of motor trajectories with PR30 binding patterns from 
different microtubules or microtubule regions within the same 
chamber preparation. This procedure led to simulated PR30 band-
ing patterns at an average density equivalent to the true patterns, 
which were used to account for the contribution of random chance 
to the frequency of colocalization events. Original and simulated 
images were assessed blind to their identities to avoid uncon-
scious bias.
Statistics
Statistical analyses and data plotting were performed using Prism 8. 
Normality of the data was tested using the D’Agostino & Pearson 
normality test. Data containing more than two groups showing 
normal distribution were analyzed with a one-way analysis of vari-
ance (ANOVA) test and Tukey post hoc test. Data that were not 
normally distributed were analyzed using the Kruskal-Wallis non-
parametric test with Dunn’s correction for multiple comparisons. 
Data with two groups showing normal distribution were analyzed 
using Student’s t test; otherwise, the Mann-Whitney U test was 
used. A one-way ANOVA test with Dunnett’s correction was used 
for multiple comparisons to the control or Tukey’s correction when 
comparing between all conditions. A Fisher’s exact test was per-
formed when comparing categorical variables. For the data in 
Fig. 1B, a linear mixed model with random effect of subject and of 
experiment was also applied and confirmed significance. *P < 0.05, 
**P < 0.01, ***P < 0.001, and ****P < 0.0001 were considered signif-
icant. Data values represent means ± SD, unless indicated otherwise.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/15/eabg3013/DC1
View/request a protocol for this paper from Bio-protocol.
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